Financial & Business, Supplier News

FineLine Technologies Acquires Digi-Trax, Creates Healthcare Division

Digi-Trax adds advanced labeling and identification solutions for blood collection, cellular therapy, clinical laboratory specimen labeling.

Author Image

By: Sam Brusco

Associate Editor

The RepliTrax standalone barcode label replication system. Photo: FineLine Technologies

FineLine Technologies has acquired Digi-Trax, a provider of healthcare labeling and identification solutions for the blood and cell-therapy supply network. Digi-Trax will operate as FineLine’s new Healthcare division.

The company’s software and hardware solutions meet ISBT-128 international standards for coding and labeling blood, tissues, cell samples, and other products of human origin. They integrate with multiple health IT platforms and lab information systems. The set of acquired offerings include the:

  • HemaTrax ISBT-compliant labeling system
  • HemaTrax-CT on-demand print solution for ISBT 128 cellular therapy labeling
  • RepliTrax standalone barcode replication system

“We look forward to leveraging Digi-Trax’s expertise to drive growth and expand our presence in the global healthcare sector,” said FineLine CEO George Hoffman. “Digi-Trax has an outstanding 40-year legacy of customer service and continuous innovation. Together we will offer customers an all-in-one labeling solution—from barcode hardware and supplies to software.”

FineLine provides a global RFID tag, label, and packaging portfolio with a large U.S. printing and encoding capacity. It’s service bureau network manages the fulfillment process from data processing and quality control to packaging and distribution.

“We’re excited about this next phase for Digi-Trax. Operating as a FineLine company, Digi-Trax will leverage FineLine’s scale, robust global infrastructure and large vendor network,” said Jeff Kriozere, Digi-Trax owner and son of the company’s founder. “FineLine is the perfect partner to help us further enable hospitals, blood centers and cell therapy facilities to maintain regulatory compliance while improving operational efficiency. Our team remains dedicated to providing the same outstanding products, service and support that our customers have come to expect. This transition allows us to build on our legacy while continuing to innovate for the future. I look forward to remaining with the company and continuing to lead the organization into its next chapter.”

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters